Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial
Progress in Cardiovascular Diseases · 2024-07 · 85 · 74-81
DOI: 10.1016/j.pcad.2024.02.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Progress in Cardiovascular Diseases, 2024-07. Verfasst von Estíbaliz Díaz-Balboa und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of A Coruña, Department of Physiotherapy, Medicine and Biomedical Sciences, Campus de Oza, A Coruña 15071, Spain; Cardiology Department, U…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Cardiac Rehabilitation, Cardio-Oncology. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundación Científica de la Asociación Española Contra el Cáncer, Instituto de Salud Carlos III.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Breast cancer (BC) treatment with anthracyclines and/or anti-human epidermal growth factor receptor-2 (HER2) antibodies is associated with an increased risk of cardiovascular disease complications, including cancer therapy-related cardiac dysfunction (CTRCD). While Cardio-Oncology Rehabilitation (CORe) programs including exercise have emerged to minimize these risks, its role in preventing CTRCD is unclear. OBJECTIVES: We investigated the effectiveness of an exercise-based CORe program in preventing CTRCD [left ventricular ejection fraction (LVEF) drop ≥10% to a value 15% in global longitudinal strain (GLS)]. Secondary outcomes examined changes in cardiac biomarkers, physical performance including peak oxygen consumption, psychometric and lifestyle outcomes. Safety, adherence, and patient satisfaction were also assessed. METHODS: This is a randomized controlled trial including 122 early-stage BC women receiving anthracyclines and/or anti-HER2 antibodies, randomized to CORe (n = 60) or usual care with exercise recommendation (n = 62). Comprehensive assessments were performed at baseline and after cardiotoxic treatment completion. The average duration of the intervention was 5.8 months. RESULTS: No cases of CTRCD were identified during the study. LVEF decreased in both groups, but was significantly attenuated in the CORe group [-1.5% (-2.9, -0.1); p = 0.006], with no changes detected in GLS or cardiac biomarkers. The CORe intervention led to significant body mass index (BMI) reduction (p = 0.037), especially in obese patients [3.1 kg/m2 (1.3, 4.8)]. Physical performance and quality-of-life remained stable, while physical activity level increased in both groups. No adverse events were detected. CONCLUSIONS: This study suggests that CORe programs are safe and may help attenuate LVEF decline in BC women receiving cardiotoxic therapy and reduce BMI in obese patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of A Coruña, Department of Physiotherapy, Medicine and Biomedical Sciences, Campus de Oza, A Coruña 15071, Spain; Cardiology Department, University Clinical Hospital of Santiago de Compostela (SERGAS); Centro…
- Cardiology Department, University Clinical Hospital of Santiago de Compostela (SERGAS); Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 15706 Santiago de Compostela, A Coruña, Spain;…
- University of A Coruña. Psychosocial Intervention and Functional Rehabilitation Research Group, Department of Physiotherapy, Medicine and Biomedical Sciences, Campus de Oza, A Coruña, Spain 15071. Electronic address: be…
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga 29010, Spain; Department of Physiotherapy, University of Málaga, Málaga 29071, Spain. Electronic address: ac…
- Unit of Biostatistics, Department of Statistics, Mathematical Analysis, and Optimization, Universidade de Santiago de Compostela, Spain. Electronic address: oscar.lado.baleato@sergas.es.
- Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, A Coruña, Spain; Medical Oncology Department and Translational Medical Oncology Group, University Clinical Hospital of Santiago (…
Förderung
- Fundación Científica de la Asociación Española Contra el Cáncer
- Instituto de Salud Carlos III
Zitieren
APA
Díaz-Balboa, E., Peña-Gil, C., Rodríguez-Romero, B., Cuesta-Vargas, A. I., Lado-Baleato, O., Martínez-Monzonís, A., Pedreira-Pérez, M., Palacios-Ozores, P., López-López, R., González-Juanatey, J. R., & González-Salvado, V. (2024). Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial. Progress in Cardiovascular Diseases, 85, 74-81. https://doi.org/10.1016/j.pcad.2024.02.002
Vancouver
Díaz-Balboa E, Peña-Gil C, Rodríguez-Romero B, Cuesta-Vargas AI, Lado-Baleato O, Martínez-Monzonís A, et al. Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial. Progress in Cardiovascular Diseases. 2024;85:74-81. doi:10.1016/j.pcad.2024.02.002
BibTeX
@article{DazBalboa2024,
author = {Díaz-Balboa, Estíbaliz and Peña-Gil, Carlos and Rodríguez-Romero, Beatriz and Cuesta-Vargas, Antonio I and Lado-Baleato, Oscar and Martínez-Monzonís, Amparo and Pedreira-Pérez, Milagros and Palacios-Ozores, Patricia and López-López, Rafael and González-Juanatey, José R and González-Salvado, Violeta},
title = {Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial},
journal = {Progress in Cardiovascular Diseases},
year = {2024},
volume = {85},
pages = {74--81},
doi = {10.1016/j.pcad.2024.02.002}
}
EUVIMED